Byakangelicol

Synonyms: 白当归脑
Byakangelicol 是一种具有口服活性且可穿透血脑屏障的呋喃香豆素,具有抗肿瘤作用,通过诱导 ROS 积累、诱导线粒体途径的细胞凋亡 (apoptosis) 和细胞周期阻滞,其机制涉及 JNK/p38 的上调和 AKT、ERK 和 STAT3 等信号通路的下调,同时可下调 TLR3/TLR4/MyD88/SARM1/NF-κB 以减少小胶质细胞活化与神经炎症,并通过抑制 COX-2 表达、调控巨噬细胞极化、抑制 NF-κB 信号通路有效破坏破骨细胞的活化和炎症反应,可用于肝癌、缺血性脑卒中和假体周围溶骨症相关研究。
产品编号: MS-I37718 纯度: 98.66% CAS No.: 26091-79-2 分子式: C17H16O6 分子量: 316.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Byakangelicol 是一种具有口服活性且可穿透血脑屏障的呋喃香豆素,具有抗肿瘤作用,通过诱导 ROS 积累、诱导线粒体途径的细胞凋亡 (apoptosis) 和细胞周期阻滞,其机制涉及 JNK/p38 的上调和 AKT、ERK 和 STAT3 等信号通路的下调,同时可下调 TLR3/TLR4/MyD88/SARM1/NF-κB 以减少小胶质细胞活化与神经炎症,并通过抑制 COX-2 表达、调控巨噬细胞极化、抑制 NF-κB 信号通路有效破坏破骨细胞的活化和炎症反应,可用于肝癌、缺血性脑卒中和假体周围溶骨症相关研究。

生物实验数据

生物活性 Byakangelicol is an orally active furanocoumarin capable of crossing the blood-brain barrier that exerts antitumor effects by inducing ROS accumulation, mitochondrial apoptosis, and cell cycle arrest through mechanisms involving upregulation of JNK/p38 and downregulation of signaling pathways such as AKT, ERK, and STAT3, while also downregulating TLR3/TLR4/MyD88/SARM1/NF-κB to reduce microglial activation and neuroinflammation, and effectively disrupting osteoclast activation and inflammatory responses by inhibiting COX-2 expression, modulating macrophage polarization, and suppressing NF-κB signaling, making it applicable for research on liver cancer, ischemic stroke, and periprosthetic osteolysis.
IC50 & Target

COX-2

 

NF-κB

 

TLR3

 

TLR4

 

STAT3

 

体外研究
(In Vitro)

Byakangelicol (20-100 μM; 24-96 h) 对 HepG2、Hep3B 和 Huh-7 肝癌 (HCC) 细胞具有剂量和时间依赖性的细胞毒性,其 IC50 值范围为 49 至 58 μM,而对正常人源细胞 GES-1、IMR-90 和 293T 的细胞毒性较低。
Byakangelicol (49 μM; 12-72 h) 可诱导 HepG2 细胞呈时间依赖性凋亡,凋亡细胞占比提升 30.37%,且该效应可被 NAC 预处理逆转。
Byakangelicol (49 μM; 12-72 h) 可使 HepG2 细胞的线粒体膜电位降低 18.30%。
Byakangelicol (49 μM; 12-72 h) 可在 HepG2 细胞中诱导细胞内 ROS 呈时间依赖性累积。
Byakangelicol (49 μM; 12-72 h) 可将 HepG2 细胞阻滞于 G2/M 期,使该期细胞比例从 18.87%升高至 31.49%,且该效应可被 NAC 预处理逆转。
Byakangelicol (49 μM; 12-72 h) 以时间依赖的方式抑制 HepG2 细胞迁移,且该效应可被 NAC 预处理逆转。
Byakangelicol (49 μM; 12-72 h) 可调控 HepG2 细胞中的蛋白表达,从而诱导线粒体依赖性凋亡、调控 AKT/MAPK/STAT3 通路、诱导 G2/M 期阻滞,并通过 ROS 介导的机制抑制细胞迁移;而预先使用 NAC 或 MAPK 抑制剂可逆转上述作用。
Byakangelicol (0.01-100 μM; 24 h) 在孵育 24 小时后,于 ≤10 μM 的浓度下对 RAW264.7 细胞无毒性,但在 50 和 100 μM 浓度下表现出细胞毒性。
Byakangelicol (5-10 μM) 可浓度依赖性地抑制 RAW264.7 细胞中由 TiPs 刺激、RANKL 诱导的破骨细胞形成,其中 10 μM 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM; 8 days) 可浓度依赖性地抑制 RAW264.7 细胞在牛骨切片上由 TiPs 刺激、RANKL 诱导的骨吸收,其中 10 μM 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 COX-2、MMP9 和 NFATc1 蛋白表达上调,其中 10 μM 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 IL-1β、TNF-α 和 IL-6 蛋白表达上调,其中 10 μM 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 刺激的 NF-κB 通路激活,其中 10 μM 对 P-P65 和 P-IKBα 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 COX-2、MMP9 和 NFATc1 mRNA 表达上调,其中 10 μM 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM) 呈浓度依赖性抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 IL-1β、TNF-α 和 IL-6 mRNA 表达上调,其中 10 μM 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM; 24 h) 可浓度依赖性地抑制 TiPs 诱导的 M1 极化,并恢复经 RANKL 处理的 RAW264.7 细胞中 M2 标记蛋白的表达,其中 10 μM 对 iNOS 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM; 24 h) 可浓度依赖性地抑制 TiPs 诱导的 M1 极化,并恢复经 RANKL 处理的 RAW264.7 细胞中 M2 标志物的 mRNA 表达,其中 10 μM 对 iNOS 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM; 24 h) 可浓度依赖性地抑制 TiPs 刺激的 M1 极化,并恢复经 RANKL 处理的 RAW264.7 细胞中 M2 标志物的荧光强度,其中 10 μM 对 iNOS 的抑制作用强于 5 μM。
Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 P65 核转位。

Cell Cytotoxicity Assay

Cell Line: HepG2, Hep3B, Huh-7, GES-1, IMR-90, 293T
Concentration: 20, 40, 60, 80, 100 μM
Incubation Time: 24, 48, 72, 96 h
Result: Showed dose- and time-dependent cytotoxicity against HepG2, Hep3B, and Huh-7 cells, with significantly stronger killing effects than 5-FU.
Exhibited IC50 values of 49 μM for HepG2 cells, 52 μM for Hep3B cells, and 58 μM for Huh-7 cells.
Showed lower cytotoxicity to normal GES-1, IMR-90, and 293T cells compared to 5-FU.

Apoptosis Analysis

Cell Line: HepG2
Concentration: 49 μM
Incubation Time: 12, 24, 48, 72 h
Result: Increased the percentage of apoptotic HepG2 cells in a time-dependent manner, reaching a 30.37% increase after 72 h of treatment.
Reduced the apoptosis rate from 24.57% to 9.87% when cells were pretreated with NAC.

Cell Cycle Analysis

Cell Line: HepG2
Concentration: 49 μM; 49 μM with 10 mM NAC pretreatment
Incubation Time: 12, 24, 48, 72 h; 24 h (NAC pretreatment)
Result: Increased the proportion of HepG2 cells in the G2/M phase in a time-dependent manner, rising from 18.87% to 31.49% after 72 h of treatment.
Reversed the G2/M phase proportion increase from 31.35% to 18.72% when cells were pretreated with NAC.

Cell Migration Assay

Cell Line: HepG2
Concentration: 49 μM; 49 μM with 10 mM NAC pretreatment
Incubation Time: 12, 24, 48, 72 h; 72 h (NAC pretreatment, wound healing); 24 h (NAC pretreatment, protein analysis)
Result: Reduced HepG2 cell migration in a time-dependent manner, with migration ability progressively decreasing over 72 h.
Accelerated cell migration, reversing the inhibitory effect of Byakangelicol, when cells were pretreated with NAC.

Western Blot Analysis

Cell Line: HepG2
Concentration: 49 μM; 49 μM with 10 μM MAPK inhibitors (FR180204, SP600125, SB203580) pretreatment; 49 μM with 10 mM NAC pretreatment
Incubation Time: 12, 24, 48, 72 h; 24 h (MAPK inhibitors pretreatment); 24 h (NAC pretreatment)
Result: Increased expression of pro-apoptotic proteins cyto-c, Bad, cle-casp-3, and cle-PARP, and decreased expression of anti-apoptotic protein Bcl-2 in a time-dependent manner.
Increased phosphorylated JNK and p38 expression, and decreased phosphorylated AKT, ERK, and STAT3 expression in a time-dependent manner.
Reversed changes in signaling pathway protein phosphorylation, and reduced cle-casp-3 and cle-PARP expression when cells were pretreated with NAC.
Increased expression of p21 and p27, and decreased expression of CDK1/2 and Cyclin B in a time-dependent manner; NAC pretreatment reversed these changes.
Decreased phosphorylated AKT and GSK-3β expression, increased E-cadherin expression, and decreased N-cadherin and β-catenin expression in a time-dependent manner; NAC pretreatment reversed these changes.
Reversed changes in signaling pathway protein phosphorylation when cells were pretreated with MAPK inhibitors.

Cell Cytotoxicity Assay

Cell Line: RAW264.7 mouse osteoclast precursor cells
Concentration: 0.01-100 μM
Incubation Time: 24 h
Result: Exhibited no significant cytotoxicity at concentrations below 10 μM.
Significantly reduced cell viability at concentrations of 50 μM and 100 μM.

Western Blot Analysis

Cell Line: RAW264.7 mouse osteoclast precursor cells stimulated with RANKL and TiPs
Concentration: 5 and 10 μM
Incubation Time: 24 h
Result: Reversed TiPs-induced increase in iNOS protein expression and decrease in ARG1 protein expression in a concentration-dependent manner.
Reduced iNOS expression and restored ARG1 expression at 5 μM and 10 μM.
Showed greater inhibition of iNOS expression at 10 μM than at 5 μM.

Real Time qPCR

Cell Line: RAW264.7 mouse osteoclast precursor cells stimulated with RANKL and TiPs
Concentration: 5 and 10 μM
Incubation Time: 24 h
Result: Reversed TiPs-induced increase in iNOS mRNA expression and decrease in ARG1 mRNA expression in a concentration-dependent manner.
Reduced iNOS expression and restored ARG1 expression at 5 μM and 10 μM.
Showed greater inhibition of iNOS expression at 10 μM than at 5 μM.

Immunofluorescence

Cell Line: RAW264.7 mouse osteoclast precursor cells stimulated with RANKL and TiPs
Concentration: 5 and 10 μM
Incubation Time: 24 h
Result: Reversed TiPs-induced increase in iNOS fluorescence intensity and decrease in ARG1 fluorescence intensity in a concentration-dependent manner.
Reduced iNOS fluorescence and restored ARG1 fluorescence at 5 μM and 10 μM.
Showed greater inhibition of iNOS fluorescence at 10 μM than at 5 μM.
体内研究
(In Vivo)

Byakangelicol (25 mg/kg;口服;每日 1 次;术后 30 分钟开始,连续 3 天) 在 25 mg/kg 剂量下对小鼠缺血性卒中发挥更优的神经保护作用,可显著缩小皮质梗死体积,抑制神经元凋亡,改善运动功能,抑制小胶质细胞增殖及促炎极化,通过 TLR3/TLR4/MyD88/SARM1/NF-κB 通路减轻神经炎症,并通过上调内源性抗氧化酶缓解氧化应激。
Byakangelicol (1 mg/kg/天;颅骨局部注射;每周 3 次;共 28 天) 可通过减少破骨细胞形成、恢复骨形态计量学参数正常水平,并将巨噬细胞极化从促炎 M1 表型转向其他方向,有效缓解 TiPs 诱导的雄性 C57BL/6 小鼠颅部假体周围骨溶解,且观察到成熟破骨细胞数量减少近 50%。

Animal Model: ICR (7-week-old, 25-30 g)
Dosage: 10 mg/kg; 25 mg/kg
Administration: p.o.; once daily; 3 days (starting 30 minutes post-surgery)
Result: Reduced ischemia-induced cortical infarction volume, with the 25 mg/kg dose showing a more significant reduction in stroke volume percentage compared to vehicle controls.
Significantly decreased the number of TUNEL+ apoptotic cells in the infarct core at 25 mg/kg compared to vehicle and 10 mg/kg groups.
Improved forelimb dysfunction at 25 mg/kg, as shown by reduced left paw contact asymmetry in the cylinder test and reduced right forelimb foot faults in the grid walking test, compared to vehicle and 10 mg/kg groups.
Significantly decreased the number of Iba-1+ microglia and Iba-1+/BrdU+ proliferating microglia, and reduced Iba-1 protein expression in the infarct core at 25 mg/kg compared to vehicle controls.
Decreased the number of iNOS+/Iba-1+ pro-inflammatory microglia and increased the number of CD206+/Iba-1+ anti-inflammatory microglia in the infarct core at 25 mg/kg; also reduced iNOS protein and mRNA (iNOS, CD32) levels, and increased CD206 protein and mRNA (CD206, Ym1/2) levels compared to vehicle controls.
Reduced protein levels of pro-inflammatory cytokines TNF-α and IL-1β, and increased protein levels of anti-inflammatory cytokines TGF-β and IL-10 in the infarct core at 25 mg/kg compared to vehicle controls.
Reduced protein levels of TLR3, TLR4, p-NF-κB, MyD88, and SARM1 in the infarct core at 25 mg/kg compared to vehicle controls.
Decreased immunoreactivity of oxidative stress markers 8-OHdG and 4-HNE, and increased immunoreactivity and protein levels of antioxidant enzymes SOD1, SOD2, and GPX1 in the infarct core at 25 mg/kg compared to vehicle controls.
Animal Model: C57BL/6 (8-week-old male, cranial osteolysis induced by Ti particles implantation on skull surface)
Dosage: 1 mg/kg/day
Administration: local skull injection; three times weekly; duration of the study
Result: Increased bone mineral density compared to the TiPs-only group.
Restored bone volume per total volume and trabecular number.
Reduced the number of lytic pores in calvariae.
Attenuated TiPs-induced calvarial erosion.
Reduced TRAP-positive mature osteoclasts by nearly 50%.
Decreased the number of MMP9- and NFATc1-positive osteoclast marker cells.
Suppressed TiPs-induced COX-2 expression.
Reduced levels of M1 macrophage markers iNOS and IL-1b.
Reversed the TiPs-induced decrease in M2 macrophage marker ARG1 in calvarial tissues.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 316.31
分子式 C17H16O6
CAS No. 26091-79-2
别名 白当归脑

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 5 mg/mL (15.81 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (158.07 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.1615 mL15.8073 mL31.6146 mL79.0364 mL
5 mM0.6323 mL3.1615 mL6.3229 mL15.8073 mL
10 mM0.3161 mL1.5807 mL3.1615 mL7.9036 mL
15 mM0.2108 mL1.0538 mL2.1076 mL5.2691 mL
20 mM0.1581 mL0.7904 mL1.5807 mL3.9518 mL
25 mM0.1265 mL0.6323 mL1.2646 mL3.1615 mL
30 mM0.1054 mL0.5269 mL1.0538 mL2.6345 mL
40 mM0.0790 mL0.3952 mL0.7904 mL1.9759 mL
50 mM0.0632 mL0.3161 mL0.6323 mL1.5807 mL
60 mM0.0527 mL0.2635 mL0.5269 mL1.3173 mL
80 mM0.0395 mL0.1976 mL0.3952 mL0.9880 mL
100 mM0.0316 mL0.1581 mL0.3161 mL0.7904 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

白当归脑 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础